# Atrasentan in Patients With IgA Nephropathy

Study · id `cardio:ct-nct04573478` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04573478](<https://clinicaltrials.gov/study/NCT04573478>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04573478

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 404 participants.

## Technical summary

Registry record NCT04573478. Randomized; double masking; primary purpose treatment. Start 2020-12-11 (actual); primary completion 2028-04-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 404 participants (enrolled count; ClinicalTrials.gov record NCT04573478, source copy `cardio:ctgov-nct04573478-2026-06-04`, retrieved 2026-10-31)
- Started: 2020-12-11 (actual) (ClinicalTrials.gov record NCT04573478, source copy `cardio:ctgov-nct04573478-2026-06-04`, retrieved 2026-10-31)
- Primary completion: 2028-04-14 (anticipated) (ClinicalTrials.gov record NCT04573478, source copy `cardio:ctgov-nct04573478-2026-06-04`, retrieved 2026-10-31)
- Completion: 2028-04-14 (anticipated) (ClinicalTrials.gov record NCT04573478, source copy `cardio:ctgov-nct04573478-2026-06-04`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Brazil; Canada; China; Colombia; France; Germany; Hong Kong SAR China; India; Italy; Japan; New Zealand; Poland; Portugal; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT04573478, source copy `cardio:ctgov-nct04573478-2026-06-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04573478-2026-06-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Atrasentan in Patients With IgA Nephropathy
- Acronym: ALIGN
- Condition: IgA Nephropathy
- Condition: Immunoglobulin A Nephropathy
- Intervention (Drug): Atrasentan
- Intervention (Drug): Placebo
- Intervention (Drug): Zigakibart
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 352918d5bff9c80a5e37b4f0463f0252357d8bc63102df7b8330b532db15f101
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
